跳转至内容
Merck
CN

P0053

PGLa

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C88H162N26O22S
化学文摘社编号:
102068-15-5
分子量:
1968.45
UNSPSC Code:
51102829
NACRES:
NA.85

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI

1S/C88H162N26O22S/c1-19-48(9)69(113-78(126)52(13)97-66(117)42-95-72(120)50(11)98-79(127)59(31-23-27-36-91)108-85(133)64(44-115)111-77(125)54(15)100-81(129)61(33-38-137-18)104-65(116)41-93)87(135)101-51(12)73(121)96-43-67(118)105-57(29-21-25-34-89)82(130)114-70(49(10)20-2)88(136)103-55(16)74(122)106-60(32-24-28-37-92)83(131)112-68(47(7)8)86(134)102-56(17)76(124)110-63(40-46(5)6)84(132)107-58(30-22-26-35-90)80(128)99-53(14)75(123)109-62(71(94)119)39-45(3)4/h45-64,68-70,115H,19-44,89-93H2,1-18H3,(H2,94,119)(H,95,120)(H,96,121)(H,97,117)(H,98,127)(H,99,128)(H,100,129)(H,101,135)(H,102,134)(H,103,136)(H,104,116)(H,105,118)(H,106,122)(H,107,132)(H,108,133)(H,109,123)(H,110,124)(H,111,125)(H,112,131)(H,113,126)(H,114,130)/t48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-,64-,68-,69-,70-/m0/s1

InChI key

PJRSUKFWFKUDTH-JWDJOUOUSA-N

form

solid

solubility

H2O: 1 mg/mL

antibiotic activity spectrum

Gram-negative bacteria, fungi, viruses

mode of action

cell membrane | interferes

storage temp.

2-8°C

Quality Level

200

General description

化学结构：肽

Application

PGLa是一种阳离子抗菌肽(AMP)，最初从青蛙中分离得到。它已经被证明有抗菌，1 抗真菌，2和抗病毒，3 活性。 它被用来研究新的肽片段，来自PGLa和非洲爪蟾多核胃粘膜细胞。

Biochem/physiol Actions

PGLa的前体是蛙皮素和爪蟾肽。 PGLa对革兰氏阴性细菌的作用机制是破坏细胞脂质双层膜。4 它可用于诱导脂双层和细菌细胞膜中的跨膜孔形成。 它与蛙皮素2结合使用可产生协同效应。

Other Notes

500ug
保存于密闭容器内，置于干燥通风处。

存储类别

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
SLBQ7151V
SLBN9420V
SLBN5121V
SLBD6810V
SLBC8846V

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Karl Lohner et al.
Biochimica et biophysica acta, 1788(8), 1656-1666 (2009-06-02)
Peptidyl-glycine-leucine-carboxyamide (PGLa), isolated from granular skin glands of Xenopus laevis, is practically devoid of secondary structure in aqueous solution and in the presence of zwitterionic phospholipids, when added exogenously, but adopts an alpha-helix in the presence of anionic lipids. The
Marco Ieronimo et al.
Journal of the American Chemical Society, 132(26), 8822-8824 (2010-06-17)
(19)F NMR is a unique tool to examine the structure of fluorine-labeled peptides in their native cellular environment, due to an exquisite sensitivity and lack of natural abundance background. For solid-state NMR analysis, we isolated native membranes from erythrocyte ghosts
Mareike Hartmann et al.
Antimicrobial agents and chemotherapy, 54(8), 3132-3142 (2010-06-10)
Scanning electron microscopy (SEM) and transmission electron microscopy (TEM) were used to examine the ultrastructural changes in bacteria induced by antimicrobial peptides (AMPs). Both the beta-stranded gramicidin S and the alpha-helical peptidyl-glycylleucine-carboxyamide (PGLa) are cationic amphiphilic AMPs known to interact
Sameer A Ansari et al.
Journal of neurointerventional surgery, 3(4), 324-330 (2011-10-13)
Bioactive polyglycolic/polylactic acid (PGLA)-coated Matrix detachable coils were reported to incite intra-aneurysmal inflammation and fibrosis. Multiple large case series with Matrix-1 coils have shown no advantage with respect to aneurysm recurrence. Second-generation Matrix-2 coils were designed with improved platinum support
Theodore Parker et al.
Journal of biomedical materials research. Part B, Applied biomaterials, 100(3), 603-610 (2012-01-31)
Sustained release formulations of a potent antithrombotic drug, cilostazol, in poly-(lactic acid-co-glycolic acid) (PLGA) matrices were created for luminal release from a novel drug-eluting stent utilizing reservoirs (RES TECHNOLOGY™). The crystallinity of cilostazol and the morphology of the cilostazol/polymer matrix
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持